In a groundbreaking study published in BME Frontiers, researchers from the University of California, Los Angeles (UCLA), in ...
In a groundbreaking study published in BME Frontiers, researchers from the University of California, Los Angeles (UCLA), in collaboration with ...
With respect to assay development, quality assurance and, ultimately, clinical adoption, the primary subject of this review, these advantages are critical. Implicit with these advantages, TMAs enable ...
Researchers from the University of Turku and Turku University Hospital, Finland, led by Docent Sami Ventelä and Professor Jukka Westermarck, have identified a novel diagnostic tool that can ...
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...
For connective tissue diseases, the multiplex assay is designed to rapidly detect and identify up to 1275 disease markers per hour. Seamless, microarray-internal calibration and quality control as ...
EYSINS, Switzerland, April 3, 2025 /PRNewswire/ --Today, AliveDx announces it has submitted 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the MosaiQ AiPlex ® ...
Decipher score as a predictor of response to treatment intensification in the NRG Oncology-RTOG 0534 (SPPORT) phase III randomized post-prostatectomy salvage radiotherapy trial. Continuous MMAI scores ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results